| scholarly article | Q13442814 |
| P2093 | author name string | Chiranjeevi Sandi | |
| Mark A Pook | |||
| Sahar Al-Mahdawi | |||
| P2860 | cites work | Genome-wide prediction and identification of cis-natural antisense transcripts in Arabidopsis thaliana | Q21184167 |
| A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome | Q21562300 | ||
| DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development | Q22010765 | ||
| The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain | Q22065852 | ||
| An integrated encyclopedia of DNA elements in the human genome | Q22122150 | ||
| Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 | Q24316558 | ||
| CpG methylation, chromatin structure and gene silencing-a three-way connection | Q24533302 | ||
| Over 20% of human transcripts might form sense-antisense pairs | Q24564527 | ||
| GENCODE: the reference human genome annotation for The ENCODE Project | Q24608743 | ||
| A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression | Q24620388 | ||
| CTCF: master weaver of the genome | Q24621388 | ||
| ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS | Q24629431 | ||
| Hyperexpansion of GAA repeats affects post-initiation steps of FXN transcription in Friedreich's ataxia | Q24634126 | ||
| Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification | Q24635918 | ||
| Decitabine in the treatment of myelodysplastic syndromes | Q24641906 | ||
| Small dsRNAs induce transcriptional activation in human cells | Q24676787 | ||
| Understanding the genetic and molecular pathogenesis of Friedreich's ataxia through animal and cellular models | Q26860523 | ||
| HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model | Q27301415 | ||
| Triplet repeat-derived siRNAs enhance RNA-mediated toxicity in a Drosophila model for myotonic dystrophy | Q27342852 | ||
| Chromatin modifications and their function | Q27861067 | ||
| RNA interference | Q28131798 | ||
| Antisense starts making more sense | Q28187514 | ||
| Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes | Q28249379 | ||
| CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing | Q28249503 | ||
| LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate | Q28251155 | ||
| In search of antisense | Q28257888 | ||
| The Sir2 family of protein deacetylases | Q28266179 | ||
| A novel sequence-specific DNA binding protein which interacts with three regularly spaced direct repeats of the CCCTC-motif in the 5'-flanking sequence of the chicken c-myc gene | Q28271955 | ||
| Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion | Q28275699 | ||
| Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes | Q28297330 | ||
| Boundaries between chromosomal domains of X inactivation and escape bind CTCF and lack CpG methylation during early development | Q28304098 | ||
| Stage- and cell-specific expression of Dnmt3a and Dnmt3b during embryogenesis. | Q52114392 | ||
| HDAC inhibitors: clinical update and mechanism-based potential. | Q53333442 | ||
| Sticky DNA: self-association properties of long GAA.TTC repeats in R.R.Y triplex structures from Friedreich's ataxia. | Q55033015 | ||
| Extension of the mutation spectrum in Friedreich's ataxia: detection of an exon deletion and novel missense mutations | Q56974340 | ||
| Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase | Q57228797 | ||
| Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways | Q57982495 | ||
| A novel deletion–insertion mutation identified in exon 3 of FXN in two siblings with a severe Friedreich ataxia phenotype | Q58157164 | ||
| DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing | Q59071144 | ||
| Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia | Q73295495 | ||
| GGA*TCC-interrupted triplets in long GAA*TTC repeats inhibit the formation of triplex and sticky DNA structures, alleviate transcription inhibition, and reduce genetic instabilities | Q73813232 | ||
| Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription | Q73842935 | ||
| Silencing gene expression by targeting chromosomal DNA with antigene peptide nucleic acids and duplex RNAs | Q80092871 | ||
| CTCF binding sites promote transcription initiation and prevent DNA methylation on the maternal allele at the imprinted H19/Igf2 locus | Q80159085 | ||
| Breaking the silence in Friedreich's ataxia | Q80286140 | ||
| Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression | Q81527224 | ||
| Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression | Q39672023 | ||
| Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells | Q39783504 | ||
| Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. | Q39871548 | ||
| Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells | Q39956136 | ||
| Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways | Q39975165 | ||
| Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. | Q39985716 | ||
| The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues | Q40149163 | ||
| Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. | Q40241487 | ||
| The role of histone acetylation in SMN gene expression. | Q40437533 | ||
| Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study | Q40485362 | ||
| A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly | Q40560930 | ||
| CTCF-binding sites flank CTG/CAG repeats and form a methylation-sensitive insulator at the DM1 locus | Q40789249 | ||
| In vitro reactivation of the FMR1 gene involved in fragile X syndrome | Q40868842 | ||
| Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases | Q42109512 | ||
| Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs | Q42677869 | ||
| Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies | Q44646952 | ||
| Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases | Q44978542 | ||
| Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells | Q45092709 | ||
| Exonic deletions of FXN and early-onset Friedreich ataxia | Q45395750 | ||
| Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia | Q45857597 | ||
| DNA methylation in intron 1 of the frataxin gene is related to GAA repeat length and age of onset in Friedreich ataxia patients. | Q46520508 | ||
| Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells | Q46709814 | ||
| Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. | Q46802333 | ||
| FXN methylation predicts expression and clinical outcome in Friedreich ataxia. | Q47872898 | ||
| Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria | Q48047307 | ||
| Increased iron in the dentate nucleus of patients with Friedrich's ataxia | Q48166308 | ||
| The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins | Q48197448 | ||
| The epigenetic magic of histone lysine methylation | Q48591117 | ||
| Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model | Q28472583 | ||
| Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation | Q28609169 | ||
| Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model | Q28743986 | ||
| Functions of DNA methylation: islands, start sites, gene bodies and beyond | Q29547260 | ||
| Landscape of transcription in human cells | Q29547467 | ||
| The diverse functions of histone lysine methylation | Q29614523 | ||
| The DNA methyltransferases of mammals | Q29617317 | ||
| Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer | Q29622925 | ||
| CTCF regulates ataxin-7 expression through promotion of a convergently transcribed, antisense noncoding RNA. | Q30502612 | ||
| DNA methylation, methyltransferases, and cancer | Q30993657 | ||
| CTCF cis-regulates trinucleotide repeat instability in an epigenetic manner: a novel basis for mutational hot spot determination | Q33384414 | ||
| Bidirectional transcription directs both transcriptional gene activation and suppression in human cells | Q33384427 | ||
| Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription | Q33517116 | ||
| Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing | Q34019122 | ||
| Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters | Q34080079 | ||
| Altered microRNA regulation in Huntington's disease models | Q34146968 | ||
| Small interfering RNA-induced transcriptional gene silencing in human cells | Q34161327 | ||
| Transcribed dark matter: meaning or myth? | Q34192913 | ||
| The distribution of repressive histone modifications on silenced FMR1 alleles provides clues to the mechanism of gene silencing in fragile X syndrome | Q34275676 | ||
| Loss of methylation activates Xist in somatic but not in embryonic cells | Q34295214 | ||
| Heterochromatin and tri-methylated lysine 20 of histone H4 in animals | Q34318944 | ||
| Epigenetic regulation of mammalian genomic imprinting | Q34326896 | ||
| A rapid, noninvasive immunoassay for frataxin: Utility in assessment of Friedreich ataxia | Q34376985 | ||
| Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues | Q34399378 | ||
| Histone deacetylase inhibitors: discovery and development as anticancer agents | Q34470150 | ||
| Inhibition of c-erbA mRNA splicing by a naturally occurring antisense RNA. | Q34507857 | ||
| Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. | Q34542422 | ||
| Repeat expansion affects both transcription initiation and elongation in friedreich ataxia cells | Q34575655 | ||
| Activating gene expression in mammalian cells with promoter-targeted duplex RNAs | Q34607180 | ||
| An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals | Q34699372 | ||
| Control of developmental timing by micrornas and their targets | Q34762490 | ||
| DNA methylation status is inversely correlated with green tea intake and physical activity in gastric cancer patients | Q34930032 | ||
| Diagnosis and treatment of Friedreich ataxia: a European perspective | Q34974299 | ||
| DNA methyltransferase inhibitors-state of the art. | Q34990742 | ||
| Comprehensive DNA methylation analysis of human peripheral blood leukocytes and lymphoblastoid cell lines | Q35001966 | ||
| The molecular basis of Friedreich ataxia. | Q35075287 | ||
| Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. | Q35481748 | ||
| Histone lysine methylation: a signature for chromatin function | Q35571556 | ||
| Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia | Q35865338 | ||
| Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation | Q36039174 | ||
| A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro | Q36059529 | ||
| Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies | Q36129533 | ||
| Decitabine in myelodysplastic syndromes | Q36193468 | ||
| Epigenetic therapy of cancer: past, present and future | Q36399557 | ||
| SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome | Q36491908 | ||
| The mismatch repair system protects against intergenerational GAA repeat instability in a Friedreich ataxia mouse model | Q36566749 | ||
| Histone deacetylase inhibitors as therapeutics for polyglutamine disorders | Q36599926 | ||
| Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations | Q36658216 | ||
| Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line | Q36861718 | ||
| Dnmt1 deficiency promotes CAG repeat expansion in the mouse germline | Q36939612 | ||
| Long intronic GAA*TTC repeats induce epigenetic changes and reporter gene silencing in a molecular model of Friedreich ataxia | Q36959663 | ||
| HDAC inhibitors: a potential new category of anti-tumor agents. | Q36988435 | ||
| DNA triplexes and Friedreich ataxia | Q37062600 | ||
| Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy | Q37083755 | ||
| Molecular mechanisms of green tea polyphenols | Q37161937 | ||
| Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome | Q37203166 | ||
| Epigenetic therapy of leukemia: An update | Q37307226 | ||
| A distinct DNA-methylation boundary in the 5'- upstream sequence of the FMR1 promoter binds nuclear proteins and is lost in fragile X syndrome | Q37417853 | ||
| Silencing chromatin: comparing modes and mechanisms | Q37827337 | ||
| The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine | Q38045210 | ||
| Frataxin gene point mutations in Italian Friedreich ataxia patients | Q38299137 | ||
| Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. | Q38318863 | ||
| The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis | Q38328542 | ||
| miR-886-3p levels are elevated in Friedreich ataxia. | Q39319502 | ||
| Effects of Friedreich's ataxia GAA repeats on DNA replication in mammalian cells | Q39409253 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | Friedreich ataxia | Q913856 |
| P304 | page(s) | 852080 | |
| P577 | publication date | 2013-02-19 | |
| P1433 | published in | Genetics Research International | Q26842364 |
| P1476 | title | Epigenetics in Friedreich's Ataxia: Challenges and Opportunities for Therapy | |
| P478 | volume | 2013 |
| Q39793086 | A Potential New Therapeutic Approach for Friedreich Ataxia: Induction of Frataxin Expression With TALE Proteins |
| Q35802894 | A new cellular model to follow Friedreich's ataxia development in a time-resolved way. |
| Q35144024 | A novel GAA-repeat-expansion-based mouse model of Friedreich's ataxia |
| Q55427035 | Adding a temporal dimension to the study of Friedreich's ataxia: the effect of frataxin overexpression in a human cell model. |
| Q98735793 | Circulating Cell-Free Nucleic Acids as Epigenetic Biomarkers in Precision Medicine |
| Q92488515 | Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich's Ataxia |
| Q38219414 | Epigenetic-based therapies for Friedreich ataxia |
| Q27010153 | Epigenetics of Alzheimer's disease and frontotemporal dementia |
| Q37686297 | Fixing frataxin: 'ironing out' the metabolic defect in Friedreich's ataxia |
| Q34984786 | Friedreich ataxia patient tissues exhibit increased 5-hydroxymethylcytosine modification and decreased CTCF binding at the FXN locus |
| Q37485501 | Friedreich ataxia: metal dysmetabolism in dorsal root ganglia |
| Q38160224 | Friedreich's ataxia, frataxin, PIP5K1B: echo of a distant fracas. |
| Q28540063 | Generation and characterisation of Friedreich ataxia YG8R mouse fibroblast and neural stem cell models |
| Q40533450 | Lentivirus-meditated frataxin gene delivery reverses genome instability in Friedreich ataxia patient and mouse model fibroblasts |
| Q58051863 | Stratifying Heterogeneous Dimension of Neurodegenerative Diseases: Intervention for Stipulating Epigenetic Factors to Combat Oxidative Stress in Human Brain |
| Q59798711 | The Epigenetics of Alzheimer’s Disease: Factors and Therapeutic Implications |
| Q92834673 | The time dimension of neurodegeneration: the example of Friedreich's ataxia |
Search more.